개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Robert C / 2015 / Nivolumab in Previously Untreated Melanoma without BRAF Mutation / N Engl J Med 372:320~330
Brahmer J / 2015 / Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer / N Engl J Med 373:123~135
Borghaei H / 2015 / Nivolumab versus Docetaxel in Advanced Non squamous Non-Small-Cell Lung Cancer / N Engl J Med 373:1627~1639
Motzer RJ / 2015 / Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma / N Engl J Med 373:1803~1813
Ferris RL / 2016 / Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck / N Engl J Med 375:1856~1867
Brahmer J / 2015 / Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer / N Engl J Med 373:123~135
Borghaei H / 2015 / Nivolumab versus Docetaxel in Advanced Non squamous Non-Small-Cell Lung Cancer / N Engl J Med 373:1627~1639
Motzer RJ / 2015 / Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma / N Engl J Med 373:1803~1813
Ferris RL / 2016 / Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck / N Engl J Med 375:1856~1867
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Immune Network
2020 .02
-
Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Journal of Gynecologic Oncology
2018 .01
-
Nivolumab, Pembrolizumab의 임상적 사용 적정성, 유효성 및 안전성 평가
병원약사회지
2020 .01
-
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment
2017 .01
-
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Cancer Research and Treatment
2016 .01
-
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Journal of Pathology and Translational Medicine
2019 .01
-
Radiotherapy and immune checkpoint blockades: a snapshot in 2016
Radiation oncology journal : ROJ
2016 .01
-
고령 암환자에서의 nivolumab과 pembrolizumab의 유효성과 안전성 평가
한국임상약학회지
2020 .01
-
Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2017 .12
-
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset
Cancer Research and Treatment
2020 .01
-
Prognostic significance of programmed cell death-ligand 1 expression on immune cells and epithelialmesenchymal transition expression in patients with hepatocellular carcinoma
Annals of Surgical Treatment and Research
2023 .11
-
PD-1 억제제의 사용패턴 및 갑상선 관련 유해사례 발현 양상 분석
한국임상약학회지
2021 .09
-
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
-
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
2017 .01
-
Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
생체재료학회지
2023 .03
-
Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Annals of Dermatology
2021 .01
-
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Clinical and Molecular Hepatology
2020 .01
-
GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
Journal of Pathology and Translational Medicine
2017 .01
-
Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
Journal of Pathology and Translational Medicine
2021 .11
-
Updates to Clinical Information on Anticancer Immunotherapy
한국임상약학회지
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0